As part of the CHECKMATE 012 study, 21 patients with EGFR mutation-positive NSCLC (20 patients who received erlotinib pretreatment and 1 patient who did not receive EGFR-TKI treatment) were evaluated for safety and efficacy (68). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.